Unknown Manufacturer
MW33 is a recombinant fully human antibody to SARS-CoV-2. This antibody injection is currently being investigated against COVID-19 in the clinical trial NCT04533048 (A Clinical Study to Evaluate MW33 Injection).
MW33 is a recombinant fully human antibody to SARS-CoV-2. This antibody injection is currently being investigated against COVID-19 in the clinical trial NCT04533048 (A Clinical Study to Evaluate MW33 Injection).
The antibody MW33 targets the S protein epitope and is currently being investigated against COVID-19.
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
No patents found under this name
Patent documents usually refer to a drug by its chemical name or development code rather than its generic name, and applications are only published about 18 months after filing — so a newer drug may not appear here yet.
